secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPEL PHARMACEUTICALS INC (—)
CIK:        0001445499
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001193125-24-036588
Event type: m_and_a
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 2.01, 1.03, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Impel completes asset sale to JN Bidco for $17.5M cash; CEO departs
-------------------------------------------------------------------

- Closed sale of substantially all assets to JN Bidco LLC for $17.5M upfront cash plus contingent earnout based on net sales/licensing fees.
- Len Paolillo resigned as Interim CEO effective Feb 12, 2024; entered consulting agreement at $500/hr through June 30, 2024.
- Company remains in Chapter 11; stock delisted from Nasdaq, trades on OTC Pink under IMPLQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445499/000119312524036588/0001193125-24-036588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445499/000119312524036588/d769501d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-036588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer